SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion

Glucagon-like peptide-1 (GLP-1)-based incretin therapy is becoming central to the treatment of type 2 diabetes. Activation of incretin hormone receptors results in rapid elevation of cAMP followed by enhanced insulin secretion. However, the incretin effect may be significantly impaired in diabetes....

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Rajan, Sindhu, Torres, Jacqueline, Thompson, Michael S., Philipson, Louis H.
Format: Artigo
Jezik:Inglês
Izdano: American Physiological Society 2012
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3311292/
https://ncbi.nlm.nih.gov/pubmed/22234371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajpendo.00486.2011
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki